Navegando por Palavras-chave "anticonvulsant"

Agora exibindo 1 - 3 de 3
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Anticonvulsants to treat idiopathic restless legs syndrome: systematic review
    (Academia Brasileira de Neurologia - ABNEURO, 2008-06-01) Conti, Cristiane Fiquene [UNIFESP]; Oliveira, Márcio Moysés de [UNIFESP]; Valbuza, Juliana Spelta [UNIFESP]; Prado, Lucila Bizari Fernandes do [UNIFESP]; Carvalho, Luciane Bizari Coin de [UNIFESP]; Prado, Gilmar Fernandes do [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    BACKGROUND: Restless legs syndrome (RLS) is a sensory motor disorder characterized by a distressing urge to move the legs and sometimes also other parts of the body usually accompanied by a marked sense of discomfort or pain in the leg or other affected body part. Many treatments have been used to minimize the discomfort of the disease, among them the anticonvulsant therapy. AIM: This review aims to evaluate the efficacy and safety of anticonvulsant treatment for idiopathic RLS. METHOD: Systematic review of randomized or quasi-randomized, double blind trials on anticonvulsant treatment for RLS. Outcomes: relief of RLS symptoms, subjective and objective sleep quality, quality of life, and adverse events associated with the treatments. RESULTS: A total of 231 patients were randomized in three cross over studies and one parallel study. Three studies with carbamazepine, one with sodium valproate, and one with gabapentin, and they were very heterogeneous so we could not perform a metanalyses. CONCLUSIONS: There is no scientific evidence on RLS treatment with anticonvulsants for clinical practice.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Consequences of prolonged caffeine administration and its withdrawal on pilocarpine- and kainate-induced seizures in rats
    (Blackwell Publishing, 2005-09-01) Hoexter, Marcelo Queiroz [UNIFESP]; Rosa, Pedro S.; Tufik, Sergio [UNIFESP]; Mello, Luiz Eugenio [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Purpose: To investigate the consequences of caffeine consumption on epileptic seizures, we used the pilocarpine and the kainate models of epilepsy. We hypothesized that prolonged caffeine consumption or its withdrawal would alter adenosine levels and hence alter seizure susceptibility.Methods: We administered a 0.1% caffeine solution in the drinking water of adult male Wistar rats over a 2-week period. We challenged another group of animals with the same doses of pilocarpine or kainate 12 h after the withdrawal of the same caffeine-administration protocol.Results: This did not alter the threshold for the induction of seizures by a subconvulsant dose of pilocarpine (200 mg/kg, i.p.) or kainic acid (8 mg/kg, i.p.). Similarly, challenging another group of animals with the same doses of pilocarpine or kainate 12 h after the withdrawal of the same caffeine-administration protocol did not lead to any significant changes in seizures.Conclusions: With the pilocarpine model of epilepsy, we were not able to find any significant difference in seizure profile that could stem from either caffeine administration or its withdrawal. Despite the extensive laboratory evidence on the convulsant properties of xanthine derivatives in animal models of epilepsy, such strong evidence is lacking in clinical settings. Our current findings with the administration of caffeine at doses similar to those of daily life both support and confirm the clinical experience.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Effects of topiramate on oral dyskinesia induced by reserpine
    (Elsevier B.V., 2004-12-15) Araujo, N. P.; Abilio, V. C.; Silva, R. H.; Pereira, R. C.; Carvalho, R. C.; Gonzalez, C.; Bellot, R. G.; Castro, JPMV; Fukushiro, D. F.; Rodrigues, MSD; Chinen, C. C.; Frussa, R.; Universidade Federal de São Paulo (UNIFESP)
    Recently, we have described the antidyskinetic property of the GABA mimetic drug valproic acid on reserpine-induced oral dyskinesia, an animal model that has been related to tardive as well as acute dyskinesias, which are associated with important neuropathologies. the present study investigates the effects of different doses of the GABA mimetic anticonvulsant topiramate on the manifestation of reserpine-induced orofacial dyskinesia. Female EPM-M1 mice received two injections of control solution or of 0.5 mg/kg reserpine separated by 48 h. Twenty-four hours after the second reserpine or control solution injection, animals were acutely treated with control solution or topiramate (1, 3, 10 or 30 mg/kg) and were observed for quantification of oral dyskinesia or general activity in an open-field. in order to verify the effects of topiramate per se on oral dyskinesia or general activity, female EPM-M1 mice were acutely treated with control solution or 1, 3, 10 or 30 mg/kg topiramate and observed for quantification of oral dyskinesia and general activity. the highest dose of topiramate completely abolished the manifestation of reserpine-induced oral dyskinesia whereas the doses of 3 and 10 mg/kg significantly attenuated it. None of the doses of the anticonvulsant modified spontaneous locomotion frequency or oral movements, whereas spontaneous rearing frequency was decreased by 3, 10 and 30 mg/kg topiramate. the highest dose of topiramate did not modify general activity in reserpine-treated mice. These results support the potential therapeutic use of topiramate in the treatment of oral dyskinesias. (C) 2004 Elsevier Inc. All rights reserved.